• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BARD ACCESS SYSTEMS, INC. PORT ACCESS NEEDLE; SET, ADMINISTRATION, INTRAVASCULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BARD ACCESS SYSTEMS, INC. PORT ACCESS NEEDLE; SET, ADMINISTRATION, INTRAVASCULAR Back to Search Results
Model Number LH-0031
Device Problems Break (1069); Contamination (1120); Fluid/Blood Leak (1250)
Patient Problems Hemorrhage/Bleeding (1888); Failure of Implant (1924)
Event Date 01/30/2023
Event Type  malfunction  
Event Description
Patient was discharged home on continuous chemotherapy (blinatumomab).Mom woke patient up and saw that he was lying in a pool of medication.Blood was coming out of his line.Mother was unaware of duration of line break.Patient arrived to clinic and line break was visualized proximal to the needless endcap.Line break was on safe step needle tubing.Patient is at risk for blood stream infections due to this line break along with contamination of chemotherapy medication in the home.Patient began block 2 of blinatumomab therapy and had been receiving the continuous infusion since.He was discharged after initiation of the medicine.He was having outpatient bag changes every 72 hours.He presented for his day 8 scheduled bag change.He was brought to clinic by father who reported that when he awoke that morning, he was found to have blood leaking from his port tubing and his drug had leaked onto his pajamas.Parents were not sure how long it had been leaking as it had occurred sometime during sleep but the best estimate based on remaining volume was that it leaked for 6 hours.He had continued to tolerate the infusion well and without side effects.Upon arrival to clinic, the leak was visualized to be proximal to the line end cap.His port was deaccessed and reaccessed and central and peripheral blood cultures were obtained.Vancomycin was infused through his reaccesed port over 2 hours.He was then admitted for observation after the blinatumomab infusion was resumed to monitor tolerance.His new blinatumomab bag was hung on the day of admission.He was monitored overnight and had no signs of side effects or intolerance.He remained afebrile.His central and peripheral cultures showed no growth x 24 hours.He was stable for discharge home.He was scheduled to return to the pediatric oncology clinic for his next bag change.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PORT ACCESS NEEDLE
Type of Device
SET, ADMINISTRATION, INTRAVASCULAR
Manufacturer (Section D)
BARD ACCESS SYSTEMS, INC.
605 north 5600 west
salt lake city UT 84116
MDR Report Key16396255
MDR Text Key309745222
Report Number16396255
Device Sequence Number1
Product Code FPA
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source User Facility
Reporter Occupation Risk Manager
Type of Report Initial
Report Date 02/06/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/17/2023
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Model NumberLH-0031
Device Catalogue NumberLH-0031
Was Device Available for Evaluation? Yes
Is the Reporter a Health Professional? No
Was the Report Sent to FDA? Yes
Date Report Sent to FDA02/06/2023
Event Location Home
Date Report to Manufacturer02/17/2023
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Unknown
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age1095 DA
Patient SexMale
-
-